Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avacincaptad pegol in geographic atrophy secondary to AMD
NCT04435366Phase 3Completed
- Sponsor
- IVERIC bio
- Start
- Jun 2020
- Primary completion
- Jul 2022
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 20
01
Overview
A Phase 3 trial of avacincaptad pegol in geographic atrophy (GA), sponsored by IVERIC bio. Started Jun 2020; status: completed.
02
Drugs
avacincaptad pegol
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT04435366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435366.